Cetera Investment Advisers grew its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 199,138 shares of the company's stock after acquiring an additional 9,818 shares during the period. Cetera Investment Advisers' holdings in Sanofi were worth $9,604,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its position in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $31,000. Bessemer Group Inc. raised its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $44,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of "Buy" and an average price target of $63.33.
Read Our Latest Research Report on SNY
Sanofi Price Performance
Shares of NASDAQ SNY traded up $0.82 during midday trading on Friday, reaching $51.68. 2,724,204 shares of the company were exchanged, compared to its average volume of 2,380,900. The stock's 50-day moving average price is $53.36 and its 200-day moving average price is $51.89. The stock has a market cap of $130.56 billion, a P/E ratio of 20.76, a PEG ratio of 1.01 and a beta of 0.55. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The company's revenue was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.78 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.
Sanofi Increases Dividend
The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is presently 57.14%.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
